These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30288322)

  • 1. Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries.
    Maistat L; Kravchenko N; Reddy A
    Hepatol Med Policy; 2017; 2():9. PubMed ID: 30288322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia.
    Luhmann N; Champagnat J; Golovin S; Maistat L; Agustian E; Inaridze I; Myint WM; Butsashvili M; Bouscaillou J
    Int J Drug Policy; 2015 Nov; 26(11):1081-7. PubMed ID: 26342273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
    Maticic M; Videcnik Zorman J; Gregorcic S; Schatz E; Lazarus JV
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S14. PubMed ID: 25252635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syphilis, hepatitis C and HIV in Eastern Europe.
    Bailey H; Turkova A; Thorne C
    Curr Opin Infect Dis; 2017 Feb; 30(1):93-100. PubMed ID: 27755143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
    Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P
    Lancet; 2016 Sep; 388(10050):1228-48. PubMed ID: 27427455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of viral hepatitis care in 16 countries of Central and Eastern European Region.
    Chkhartishvili N; Holban T; Simonović Babić J; Alexiev I; Matičič M; Kowalska J; Horban A;
    Cent Eur J Public Health; 2019 Sep; 27(3):212-216. PubMed ID: 31580556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV and HCV among people who inject drugs in Central Asia.
    Walsh N; Maher L
    Drug Alcohol Depend; 2013 Nov; 132 Suppl 1():S37-40. PubMed ID: 23906997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
    Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
    Ford N; Wiktor S; Kaplan K; Andrieux-Meyer I; Hill A; Radhakrishnan P; Londeix P; Forette C; Momenghalibaf A; Verster A; Swan T
    Int J Drug Policy; 2015 Nov; 26(11):1088-93. PubMed ID: 26074094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
    Muller A; Vlahov D; Akiyama MJ; Kurth A
    Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.
    Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J
    J Hepatol; 2018 Nov; 69(5):1188-1196. PubMed ID: 29959953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.